Plandai Biotechnology, Inc. Gains Competitive Advantage With Preliminary Clinical Trial Results

NEW YORK, NY--(Marketwired - September 15, 2014) - Plandaí Biotechnology (OTCQB: PLPL) expects to begin commercial production of its green tea extract, Phytofare™ Catechin Complex, in the coming weeks when the first green tea crop of the season is ready for processing at the company's 8,000 acre Senteeko facility in South Africa. After receiving positive preliminary results from a human clinical trial that showed Plandaí's product offers ten times more bioavailability than the commercially available extract it was compared to, the company could gain a competitive advantage over other less potent extracts.

The results from the clinical trial, conducted in South Africa by North West University, will allow Plandaí to advertise exactly what consumers are looking for -- a more potent green tea extract. When consumers shop for health products, they're looking for those that have proven themselves in clinical trials, and, in turn, can boast of higher bioavailability.

Bioavailability is essentially the measure of how much of a drug or supplement is able to be absorbed into the bloodstream and how long it can remain there so that the body can realize its health benefits. In the case of Plandaí's green tea extract, the results should offer exactly what consumers want.

The benefit to those using the company's Phytofare™ Catechin Complex is that with higher bioavailability or absorption rate, the phytonutrients are in the bloodstream in greater quantities and for twice as long, and this should help the company become competitive in the market.

The global tea market is estimated at over $50 billion while Vitamin Shoppe estimates the US nutritional supplements industry alone is over $29 billion, and growing at 5.4% per year. Driven by increasingly educated consumers, with a heightened focus on living longer, feeling younger, living healthy and naturally, GNC now generates $1.2 billion online and through 6,300 retail stores, serving as a barometer of the magnitude of the market opportunity.

Plandaí provides higher bioavailability in its green tea extract by using a unique and proprietary process known as "hydrodynamic sheering" which unzips the molecules of the "live" green tea plant, releases all of the phytonutrients, and then rearranges the molecules into a biocompatible format. This process, which has now been scientifically validated in tomatoes and green tea, could potentially be utilized for all polyene-based molecules -- opening the door for Plandaí to tap the potential of many different plants that have known medical benefits.

Green tea's health benefits come from the 8 catechins, a type of antioxidant, found in the leaves of the plant. In Plandaí's clinical trial, all 8 of those catechins were present in the bloodstream versus only two found when participants used the commercial extract used in the clinical testing. Phytofare™ also provided 5 times greater absorption of those catechins, and the clinical trial found that the life span of the catechin's molecules in the bloodstream was doubled in Phytofare™.

View the preliminary results: http://www.plandaibiotech.com/bioavailability_trial_preliminary_results.pdf

About Stock Market Media Group
SMMG is a Research and Content Development IR firm offering a platform for corporate stories to unfold in the media with Reports, Interviews and Articles. SMMG is being compensated $3,500 per month by Plandai Biotechnology, Inc. for the creation of these materials. In the past, SMMG was compensated for similar activities by a third party. These prior activities occurred during the period from April 2013 through June 2014. During that period, SMMG received approximately $55,000 for its efforts. Neither SMMG nor anyone associated with it own shares in Plandai Biotechnology. For more information: www.stockmarketmediagroup.com.